Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT04029363

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
  • ICON plc Registry lists this organization as a collaborator
Registry
  • NCT NCT04029363
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Belgium, France, Germany, Poland, Singapore, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04029363. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-28 (actual); primary completion 2026-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
Condition
Mitral Regurgitation
Intervention (Device)
HighLife Transcatheter Mitral Valve Replacement
Lead sponsor
HighLife SAS (class: industry)
Collaborator
ICON plc (class: industry)

Record details

Record id
cardio:ct-nct04029363
Content hash
d58b5f55290c282ebeab51a66376f03f04af884d66ce88543a220c3eedf9b8fe